Gainers
- Zai Lab ZLAB stock increased by 21.5% to $20.14 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q1 earnings report came out yesterday.
- ZimVie ZIMV shares moved upwards by 20.28% to $18.5. The market value of their outstanding shares is at $503.5 million. The company's, Q1 earnings came out yesterday.
- Aadi Bioscience AADI shares moved upwards by 16.84% to $2.15. The company's market cap stands at $52.7 million. As per the press release, Q1 earnings came out yesterday.
- CEL-SCI CVM shares moved upwards by 14.38% to $1.59. The company's market cap stands at $85.8 million.
- Tarsus Pharmaceuticals TARS shares moved upwards by 13.94% to $42.56. The market value of their outstanding shares is at $1.6 billion. As per the press release, Q1 earnings came out yesterday.
- Embecta EMBC shares rose 13.33% to $11.64. The company's market cap stands at $670.2 million. The company's, Q2 earnings came out today.
Losers
- Tivic Health Systems TIVC shares declined by 35.8% to $0.86 during Thursday's pre-market session. The company's market cap stands at $1.2 million.
- CytomX Therapeutics CTMX shares declined by 30.32% to $2.92. The market value of their outstanding shares is at $198.9 million. As per the press release, Q1 earnings came out yesterday.
- CNS Pharma CNSP shares fell 13.84% to $0.21. The market value of their outstanding shares is at $2.1 million.
- Ironwood Pharmaceuticals IRWD shares decreased by 12.44% to $7.11. The market value of their outstanding shares is at $1.1 billion. As per the news, the Q1 earnings report came out today.
- Syra Health SYRA stock declined by 11.22% to $1.9. The company's market cap stands at $12.5 million. The company's, Q1 earnings came out today.
- Exact Sciences EXAS stock fell 10.56% to $53.2. The market value of their outstanding shares is at $9.7 billion. As per the news, the Q1 earnings report came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in